Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update

医学 肺癌 临床试验 癌症 肿瘤科 内科学 外科
作者
Afshin Dowlati,Horst-Dieter Hummel,Stéphane Champiat,M.E. Olmedo,Michael Boyer,Kai He,Neeltje Steeghs,Hiroki Izumi,Melissa L. Johnson,Tatsuya Yoshida,Hasna Bouchaab,Hossein Borghaei,Enriqueta Felip,Philipp J. Jost,Shirish M. Gadgeel,Xi Chen,Youfei Yu,Pablo Martínez,Amanda Parkes,Luis Paz‐Ares
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (29): 3392-3399 被引量:51
标识
DOI:10.1200/jco.24.00553
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported . Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, has shown durable anticancer activity and manageable safety in previously treated small cell lung cancer (SCLC) in DeLLphi-300 phase I and DeLLphi-301 phase II trials. Here, we report extended follow-up of DeLLphi-300 (median follow-up, 12.1 months [range, 0.2-34.3]) in fully enrolled cohorts treated with tarlatamab ≥10 mg dose administered once every two weeks, once every three weeks, or once on day 1 and once on day 8 of a 21-day cycle (N = 152). Overall, the objective response rate (ORR) was 25.0%; the median duration of response (mDOR) was 11.2 months (95% CI, 6.6 to 22.3), and the median overall survival (mOS) was 17.5 months (95% CI, 11.4 to not estimable [NE]). Among 17 patients receiving 10 mg tarlatamab once every two weeks, the ORR was 35.3%, the mDOR was 14.9 months (95% CI, 3.0 to NE), the mOS was 20.3 months (95% CI, 5.1 to NE), and 29.4% had sustained disease control with time on treatment ≥52 weeks. No new safety signals were identified. In modified Response Assessment in Neuro-Oncology Brain Metastases analyses, CNS tumor shrinkage of ≥30% was observed in 62.5% of patients (10 of 16) who had a baseline CNS lesion of ≥10 mm, including in a subset of patients with tumor shrinkage long after previous brain radiotherapy. In DeLLphi-300 extended follow-up, tarlatamab demonstrated unprecedented survival and potential findings of intracranial activity in previously treated SCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tina完成签到,获得积分10
刚刚
llli完成签到,获得积分10
刚刚
meta完成签到,获得积分10
5秒前
认真的可冥完成签到,获得积分10
5秒前
SnlyEng完成签到 ,获得积分10
14秒前
文文完成签到 ,获得积分10
15秒前
神也慕我谦姝完成签到,获得积分10
18秒前
钟原完成签到 ,获得积分10
21秒前
lzy完成签到 ,获得积分10
22秒前
28秒前
29秒前
2滴水完成签到,获得积分10
30秒前
Lee发布了新的文献求助10
31秒前
小静完成签到 ,获得积分10
33秒前
好好好发布了新的文献求助10
34秒前
周小篆完成签到,获得积分10
34秒前
Clover04的应助被科研通管家采纳,获得20
34秒前
Clover04的应助被科研通管家采纳,获得10
35秒前
Maestro_S的应助被科研通管家采纳,获得10
35秒前
胖胖橘完成签到 ,获得积分10
35秒前
cdercder的应助被科研通管家采纳,获得10
35秒前
亓雅丽完成签到 ,获得积分10
35秒前
36秒前
yk完成签到,获得积分10
43秒前
蒜蒜完成签到 ,获得积分10
44秒前
朱科源啊源完成签到 ,获得积分0
46秒前
香蕉觅云的应助被Cell采纳,获得10
49秒前
积极凌兰完成签到 ,获得积分10
51秒前
大气钥匙完成签到,获得积分10
57秒前
YHBBZ完成签到 ,获得积分10
58秒前
爱我不上火完成签到 ,获得积分10
58秒前
天宇完成签到,获得积分10
59秒前
vviruz完成签到,获得积分10
1分钟前
1分钟前
欧阳完成签到 ,获得积分10
1分钟前
Cell发布了新的文献求助10
1分钟前
两土日青发布了新的文献求助10
1分钟前
彭于晏的应助被好好好采纳,获得10
1分钟前
2026成功上岸完成签到 ,获得积分10
1分钟前
xia完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577468
关于积分的说明 21852573
捐赠科研通 7789024
什么是DOI,文献DOI怎么找? 3436347
关于科研通互助平台的介绍 2560154
邀请新用户注册赠送积分活动 2482995